Modality
Small Molecule
MOA
CD3xCD20
Target
FLT3
Pathway
Sphingolipid
MG
Development Pipeline
Preclinical
~Jan 2019
→ ~Apr 2020
Phase 1
~Jul 2020
→ ~Oct 2021
Phase 2
Jan 2022
→ Mar 2027
Phase 2Current
NCT03449349
802 pts·MG
2022-01→2027-03·Active
802 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-12-138mo awayEMA Filing· MG
2027-03-0811mo awayPh2 Data· MG
Trial Timeline
2022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2
P2
Active
Catalysts
EMA Filing
2026-12-13 · 8mo away
MG
Ph2 Data
2027-03-08 · 11mo away
MG
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03449349 | Phase 2 | MG | Active | 802 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8168 | Johnson & Johnson | Phase 2/3 | FLT3 | |
| LLY-1184 | Eli Lilly | NDA/BLA | C5 | |
| Zanuderotide | Novartis | Phase 1/2 | VEGF | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 | |
| Zorizanubrutinib | Novo Nordisk | Phase 1 | BTK | |
| Pexamavacamten | Daiichi Sankyo | NDA/BLA | TIGIT | |
| Sotorapivir | Moderna | Approved | FLT3 | |
| ITC-1028 | Intra-Cellular | Phase 2 | BCMA | |
| Nidaratamab | Exelixis | Phase 3 | FLT3 | |
| Cevizasiran | Acadia Pharma | Phase 1/2 | GPRC5D |